PacBio Announces Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq futures slip as tech rally pauses ahead of Warsh's speech
- Oil holds steady, on track for weekly fall on US-Iran talks stalemate
- Dollar heads for weekly gain as Warsh remarks awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Pacific Biosciences of California (PACB) PT Raised to $32 at Cowen
November 3, 2021 6:30 AM EDTCowen analyst Dan Brennan raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $32.00 (from $30.00) while maintaining a Market Perform rating.
The analyst commented, "PACB reported a good 3Q, with revenues +83% Y/Y, ~5% ahead of expectations, and service, consumables, & instrument revenues... More
